Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on the potential of a fianlimab and cemiplimab in melanoma treatment, highlighting its potential to become a backbone for future clinical trials, including those exploring triplet therapies, brain metastases, and adjuvant or neoadjuvant settings. This combination may offer a pathway to approval based on ongoing randomized clinical trials. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.